Taking a Leap in Cancer Diagnostics: Clarient Enters New Era in Molecular Tumor Testing, Drug Discovery Research

Clarient provides more than 350 diagnostic tests to assess and characterize tumors, including tests for BRAF, KRAS, and EGFR gene mutations.

Oncology & Biotech News   >   Feature Article

Zytiga Study Unblinded Following Positive Interim Analysis

A phase III study of abiraterone acetate in chemotherapy-naive patients with mCRPC has been unblinded following a positive interim analysis.

  >   Web Exclusives

Nonmalignant Late Effects Pose Heavy Burden After Hematopoietic Cell Transplant

The burden of late complications after hematopoietic cell transplantation is high, and these late effects are associated with poor health and decreased functional status.

Oncology & Biotech News   >   Clinical Trial Reports

Everolimus Plus Octreotide LAR Is Effective in Advanced Neuroendocrine Tumors

Combination therapy with everolimus and the octreotide LAR increases the median PFS in patients with advanced neuroendocrine tumors associated with carcinoid syndrome.

Oncology & Biotech News   >   Clinical Trial Reports

Nurse Navigators and Community Health Workers: Building Unique Relationships for Cancer Care, Part I of II

With the current economic strife we are facing in healthcare today, finding ways to deliver quality survivorship care for cancer patients has become a tremendous challenge for oncology nurse navigators.

OncLive Nursing   >   Nurse Navigators 101

No Increased Risk of Cardiovascular Death With Androgen Deprivation Therapy for Prostate Cancer

A meta-analysis shows no apparent association between androgen deprivation therapy and cardiovascular events and death in men with prostate cancer.

Oncology & Biotech News   >   Clinical Trial Reports

Assay Offers Molecular Analysis of Breast Cancer Risk Recurrence: Interview With Kenneth J. Bloom, MD

The options for exploring tumor biology continue to multiply amid technological advances that are making molecular testing options a routine part of oncology treatment.

Oncology Live   >   TechSectors

Genetic Counseling in Cancer Care: What Is the Role of Oncology Nurses?

If you saw a patient who was under 50 and had breast, colon, or ovarian cancer, what course of action would you recommend?

OncLive Nursing   >   Cover Story

Noteworthy Research Spans Range of Malignancies

A review of interesting presentations from ASH that will stimulate highly clinically relevant discussion regarding disease management within the realm of the hematologic malignancies.

Oncology Live   >   Conference Highlights

Vemurafenib Doubles Median Survival in Metastatic Melanoma Patients

Vemurafenib nearly doubles the median OS in more than 50% of patients with BRAF V600-mutated metastatic melanoma.

  >   Web Exclusives

Investigational Treatments for Multiple Myeloma

A closer look at 2 investigational agents, carlfilzomib and pomalidomide, that were featured at the 53rd American Society of Hematology annual meeting.

Oncology & Biotech News   >   Conference Highlights

Genetic Testing for Cancer Susceptibility: Clinical Utility, Direct-to-Consumer Marketing, and Ensuring Results Are Properly Interpreted

Although genetic testing for cancer susceptibility is a simple process of blood sampling, the interpretation of the results may be rather complicated.

OncLive Nursing   >   Nurse's Notes

Targeting HER2: Pertuzumab Puts the Spotlight on Dual Blockade Strategies

Since the discovery of the HER2/neu gene in the late 1970s, aberrations in the HER2 signaling pathway have been implicated in a wide variety of human cancers.

Oncology Live   >   Pathways

Benefits of Bevacizumab in Ovarian Cancer Clarified

Bevacizumab has failed to demonstrate statistically significant improvements in OS for women with recurrent ovarian cancer in 2 recent clinical trials.

Oncology Live   >   Specialty Focus

2 Leading Breast Cancer Researchers Discuss Emerging Anti-HER2 Therapeutics

Dennis Slamon, MD, PhD, and Carlos L. Arteaga, MD, discuss recent advances in anti-HER2 targeted therapies and the role of signaling by oncogenes.

Oncology Live   >   Pathways

Predicting Prostate Outcomes: Nomograms Help Patients Sort Options, But Caution Is Urged

With more than 240,000 new cases expected in the United States in 2012, prostate cancer is among the nation's most common tumor types.

Oncology Live   >   Cover Story

Baseline Glucose Levels in Older Women May Be Linked to Colorectal Cancer Risk

New findings suggest that increased serum glucose levels may be a risk factor for colorectal cancer in postmenopausal women.

Oncology & Biotech News   >   Clinical Trial Reports

Yearly Prostate Cancer Screening Does Not Provide Mortality Benefit

Annual prostate cancer screening does not decrease mortality from prostate cancer more than opportunistic screening.

Oncology & Biotech News   >   Clinical Trial Reports

A Family Tradition: The Personal Story Behind the Miami Breast Cancer Conference

The Miami Breast Cancer Conference has become a well-respected and well-attended gathering that specialists make a point of returning to year after year.

Oncology & Biotech News   >   Feature Article

Managing Chronic Myeloid Leukemia Treatment

Certain characteristics of patients with CML can affect therapeutic outcomes.

Conferences   >   2012 Hematologic Malignancies Congress